乳癌ワクチンの世界市場・パイプライン見通し

KuicK Researchが発行した調査報告書(KUIK70403)
◆英語タイトル:Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022
◆商品コード:KUIK70403
◆発行会社(リサーチ会社):KuicK Research
◆発行日:2016年12月
◆ページ数:190
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Multi UserUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

“Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.
The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient’s personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual’s necessities, high efficacy and safety, concept of cancer vaccine was formulated.

The best part with cancer vaccines is that they are capable of inducing “memory effect” in the immune cells. As a result, even in the absence of cancer vaccine molecule in the body, immune cells maintain their ability to search and destroy cancer cells. These memory effects are engraved on lymphocytes which keep on producing antigen long after the introduction of the initiator molecule. Pharmaceuticals companies are investing heavily in R&D segment to discover more properties of cancer vaccines. The benefits offered by cancer vaccine have poised the market to increase several folds.

At present the breast cancer vaccines are in emerging stages and this market has yet to be tapped by pharmaceutical companies. They are diverging funds towards research and development segment for advances in innovative breast cancer vaccines which will generate large amount of revenues. In recent years significant progress has been made on technological and scientific levels but still no vaccine for the treatment of breast cancer has seen market introduction in any part of the globe.

The present therapeutics available in market for breast cancer shows modest results in majority of patients which offers unexplored marketing opportunities for better innovative products to enter in competition. It is expected that more oncologists will prescribe the innovative breast cancer vaccines to their patients due to greater therapeutic effects. The higher rates of prescription would lead to high degree of market penetration and increased market share. The revenues generated in this way will encourage the pharmaceutical companies to fund new projects for the development of better breast cancer vaccines.

The first commercially available breast cancer vaccine is expected to be available in the market in next 5-7 years. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the advance stages of clinical trials which are supposed to clear the targeted end points. Market introduction of these new products are supposed to generate significant revenues for the pharmaceutical companies in coming years.

【レポートの目次】

1. What are Cancer Vaccines?

2. Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Mechanism of Breast Cancer Vaccine
3.1 Principle Strategies for Eliciting Immune System
3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity & Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

4. Global Breast Cancer Incidence
4.1 US
4.2 Europe
4.3 Asia
4.4 Rest of the World

5. Global Breast Cancer Vaccine Market Current Scenario
5.1 Unexplored Opportunity
5.2 Global Breast Cancer Vaccine Pipeline Overview

6. Need for Personalized Breast Cancer Vaccines

7. Global Breast Cancer Vaccine Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

8. Global Breast Cancer Vaccine Market Future Prospects

9. FDA Guideline for the Development & Marketing of Cancer Vaccines
9.1 Considerations for Both Early and Late Phase Clinical Trials
9.1.1 Patient Population
9.1.2 Monitoring The Immune Response
9.1.3 Biomarkers As Evidence Of Efficacy
9.1.4 Adjuvants Used To Stimulate Immune Response
9.1.5 Multi-Antigen Vaccines
9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
9.1.7 Concomitant And Subsequent Therapies
9.2 Considerations for Early Phase Clinical Trials
9.2.1 Starting Dose And Dosing Schedule
9.2.2 Booster And Maintenance Therapy
9.2.3 Dose Escalation
9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
9.3 Considerations For Late Phase Clinical Trials
9.3.1 Safety Profile From Early Phase Clinical Trials
9.3.2 Endpoints
9.3.3 Statistical Issues
9.3.4 Control Issues
9.3.5 Delayed Vaccine Effect
9.3.6 Autologous Vaccine Trials
9.3.7 Accelerated Approval Regulations

10. Global Breast Cancer Vaccine Clinical Pipeline by Company & Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III

11. Discontinued & Suspended Breast Cancer Vaccine in Clinical Pipeline by Company & Phase
11.1 Suspended
11.2 No Development Reported
11.3 Discontinued

12. Competitive Landscape
12.1 Advaxis
12.2 AlphaVax
12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Development of a Cellular Immune Response against TAA
Figure 4-1: US –Number of New Cases & Deaths of Breast Cancer, 2016
Figure 5-1: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-2: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 5-3: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-4: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 6-1: Overview of Personalized Cancer Vaccines Development
Figure 6-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 6-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 7-1: Favorable Parameters for Breast Cancer Vaccine Development
Figure 7-2: Challenges for Breast Cancer Vaccine Market
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: AlphaVax Clinical Pipeline Overview
Figure 12-3: Galena Biopharma Clinical Pipeline Overview
Figure 12-4: Generex Biotechnology Clinical Pipeline Overview
Figure 12-5: Immune Design Clinical Pipeline Overview
Figure 12-6: Imugene Clinical Pipeline Overview
Figure 12-7: Immunovaccine Clinical Pipeline Overview
Figure 12-8: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-9: NewLink Genetics Corporation Clinical Pipeline
Figure 12-10: TapImmune Clinical Pipeline Overview
Figure 12-11: ViroMed Clinical Pipeline Overview


【レポートのキーワード】

乳癌ワクチン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 乳癌ワクチンの世界市場・パイプライン見通し(Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆